ibuprofen altan 400 mg/100 ml roztwór do infuzji
altan pharma ltd. - ibuprofenum - roztwór do infuzji - 400 mg/100 ml
ibuprofen altan 600 mg/150 ml roztwór do infuzji
altan pharma ltd. - ibuprofenum - roztwór do infuzji - 600 mg/150 ml
olopatadine unimed pharma 1mg/ml krople do oczu, roztwór
unimed pharma spol. s.r.o. - olopatadini hydrochloridum - krople do oczu, roztwór - 1mg/ml
teriflunomide pharmascience 14 mg tabletki powlekane
pharmascience international limited - teriflunomidum - tabletki powlekane - 14 mg
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - chlorowodorek klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Środki przeciwzakrzepowe - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
vitaminum e medana 300 mg/ml płyn doustny
zakłady farmaceutyczne polpharma s.a. - int-rac-alfa-tocopherylis acetas - płyn doustny - 300 mg/ml
calcitonin 100 jelfa 100 j.m./ml płyn do wstrzykiwań
bausch health ireland ltd. - calcitoninum salmonis - płyn do wstrzykiwań - 100 j.m./ml
citropepsin 1 mg/g płyn doustny
bausch health ireland ltd. - pepsinum - płyn doustny - 1 mg/g
sorafenib pharmascience 200 mg tabletki powlekane
pharmascience international limited - sorafenibum - tabletki powlekane - 200 mg
dexketoprofen sopharma 50mg/ 2ml roztwór do wstrzykiwań / do infuzji
sopharma warszawa sp. z o.o. - dexketoprofenum - roztwór do wstrzykiwań / do infuzji - 50mg/ 2ml